From Lifestyle App to Clinical Platform: How HealthTech Startups Meet the Evidence Test
Von der Lifestyle-App zur klinischen Plattform: Wie HealthTech-Startups den Evidenztest bestehen
Summary
In 2025, venture capital funding is concentrating on startups with 'clinical evidence,' while lifestyle apps are losing investor focus. The evolution of Electronic Patient Records (ePA) and AI technology facilitates data utilization using FHIR standards, contributing to improved diagnostic and treatment planning accuracy.
Details
The healthcare market entered a period of structural change around 2025. Venture Capital (VC) is focusing funding on companies that can prove clinical evidence through randomized controlled trials and peer-reviewed publications. Conversely, interest in lifestyle apps that merely manage general health is diminishing. This shift is driven by the widespread adoption of Electronic Patient Records (ePA) and the maturation of advanced AI systems. ePA provides structured data access via FHIR interfaces, enabling AI models to utilize this data for diagnostics, therapy planning, and prognosis prediction. Specific technical applications include Neuro-Predict AI for early Alzheimer's detection (MRI + biomarkers), SynapseConnect for automatically converting physician notes into the FHIR standard (saving documentation time), and OncoMultiOmics for rapid treatment recommendations based on circulating tumor DNA analysis. Furthermore, studies report efficiency gains of up to 15% through ePA connectivity. These technological advancements are accelerating data utilization in clinical settings, promoting a transition toward a more evidence-based healthcare system.
Original content copyright by respective publishers